Inappropriate use of oral anticoagulants for patients with atrial fibrillation – 1-year outcomes of the Fushimi AF Registry –

Circulation Journal

Volumn 78, Issue 9, 2014, Pages 2166-2172

  Akao, Masaharu ^a   Abe, Mitsuru ^a   Chun, Yeong Hwa ^b   Esato, Masahiro ^b   Tsuji, Hikari ^c   Wada, Hiromichi ^a   Hasegawa, Koji ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b Ijinkai Takeda General Hospital   (Japan)

^c Tsuji Clinic   (Japan)

Author keywords

Anticoagulants; Atrial fibrillation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; RIVAROXABAN; TICLOPIDINE; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE REGISTRY; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; HEMORRHAGE; INAPPROPRIATE PRESCRIBING; JAPAN; MULTICENTER STUDY; REGISTER; STROKE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INAPPROPRIATE PRESCRIBING; JAPAN; MALE; REGISTRIES; STROKE;

EID: 84906819096     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0344     Document Type: Article

References (20)

1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A metaanalysis. Ann Intern Med 1999; 131: 492-501.
2. Inoue H, Nozawa T, Okumura K, Iwasa A, Lee JD, Shimizu A, et al. Attitudes of Japanese cardiologists toward anticoagulation for nonvalvular atrial fibrillation and reasons for its underuse. Circ J 2004; 68: 417-421.
3. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010; 123: 638-645.
4. Rose AJ, Ozonoff A, Grant RW, Henault LE, Hylek EM. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009; 2: 591-597.
5. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
6. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006; 37: 447-451.
7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
8. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
9. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
10. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
11. Akao M, Chun Y, Wada H, Esato M, Hashimoto T, Abe M, et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry. J Cardiol 2013; 61: 260-266.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
13. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: A report from the J-RHYTHM Registry. Circ J 2011; 75: 1328-1333.
14. Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation: The J-RHYTHM Registry study design. J Cardiol 2011; 57: 95-99.
15. Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation. Circ J 2013; 77: 2264-2270.
16. Lip GY, Lane DA. Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation: Focus on the elderly. Circ J 2013; 77: 1380-1388.
17. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
18. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
19. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-245.
20. Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation: A multicenter study of its status and infuential factors. Circ J 2011; 75: 2087-2094.